Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 0, with one abstention, in favor of recommending accelerated approval of a Perjeta® (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.
Sep 12, 2013 - Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 0, with one abstention, in favor of recommending accelerated approval of a Perjeta® (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.
Read Genentech's Press Release, here.
Read OncLive.com coverege, here.
Listen to AJMC's panel discussion, Treatment and Cost Implications of Pertuzumab and Trastuzumab, here.
Contributor: How Improved Clinical Terminology Supports Efficient, Accurate Data Analytics
February 1st 2023Developing a terminology strategy that reflects real-world practice and industry standards can help data scientists and other allied data professionals efficiently and accurately identify clinically relevant insights that help improve the health of populations and individual patients.
Read More
Promoting Health Equity and Resiliency in Trauma-Affected Communities
January 31st 2023On this episode of Managed Care Cast, we speak with Reverend Paul Abernathy, CEO of the Neighborhood Resilience Project and board member of UPMC for You, who discusses his experiences in promoting health and resiliency in trauma-affected communities, as well as challenges related to access and accessibility of care and medical mistrust.
Listen
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Risk for Adverse CVD Events Elevated Following Sepsis Survival
February 1st 2023Investigators found a higher overall health care burden among a large cohort of patients despite their recovery from sepsis, with potential long-term implications and higher risk of cardiovascular disease.
Read More
Dr Terrance Mayes and Dr Loretta Erhunmwunsee Discuss Leadership Roles for NCCN Forum on Equity
January 31st 2023Terrance Mayes, EdD, and Loretta Erhunmwunsee, MD, FACS, discuss their new roles as chair and vice-chair, respectively, of the National Comprehensive Cancer Network’s (NCCN) new Diversity, Equity, & Inclusion (DEI) Directors Forum.
Read More
2 Clarke Drive
Cranbury, NJ 08512